ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01650506
Recruitment Status : Completed
First Posted : July 26, 2012
Last Update Posted : August 30, 2017
Sponsor:
Collaborators:
Susan G. Komen Breast Cancer Foundation
Astellas Pharma Inc
Information provided by (Responsible Party):
Kevin Kalinsky, Columbia University

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2016
  Actual Study Completion Date : June 2016